leadf
logo-loader
viewAnteris Technologies Ltd

Admedus enters agreement opening sales channel to 1,500 hospitals

Admedus was one of only two companies awarded the purchasing agreement.

Heart puzzle being operated on
The agreement means Admedus will share in an estimated $US5.2 million annual spend

Admedus Ltd (ASX:AHZ) has entered a purchasing agreement allowing it to promote its flagship ADAPT® tissue products, CardioCel® and VascuCel®, to more than 1,500 hospitals.

CardioCel and VascuCel are used to treat heart defects and for heart valve, vessel and cardiovascular repairs.

WATCH: Admedus Ltd moving up the value chain and preparing for 'pivotal' year

The purchasing agreement will last three years and takes effect from 1 April 2018.

Direct access to more than 1,500 hospitals

The purchasing agreement is with a major Group Purchasing Organisation (GPO) in the US.

It provides Admedus direct access to promote CardioCel and VascuCel to more than 1,500 hospitals who are members of the GPO’s purchasing network.

Notably, this network has an estimated purchasing power of $US35 billion.

Delivers on company’s strategy to expand market share

Wayne Paterson, CEO, said: “This agreement is a significant opportunity for Admedus and delivers on a commitment that was made at our AGM in November 2017 to expand our market share in the US through a partnership with a major compliant GPO.

“In our most recent financial report we signalled aggressive US growth targets for 2018 and this agreement strengthens our ability to achieve that.”

Admedus is one of only two parties awarded the agreement

Admedus is one of only two parties awarded a purchasing agreement to share the estimated $US5.2 million per annum spend.

This agreement demonstrates the quality of the ADAPT® line of products, which in turn highlights the future value they can generate for Admedus shareholders.

READ: Admedus secures regulatory approval in Canada for heart tissue products

Quick facts: Anteris Technologies Ltd

Price: 3.99 AUD

ASX:AVR
Market: ASX
Market Cap: $23.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read